Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: Axicabtagene Ciloleucel
- biological: Brexucabtagene Autoleucel
- biological: KITE-585
- biological: KITE-718
- biological: KITE-439
- biological: KITE-222
- biological: KITE-363
Eligibility
Inclusion Criteria:
- The individual must have received an infusion of gene-modified cells in a completed
Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or
completed the post-treatment follow-up period in the parent study, as applicable
- The individual must understand and voluntarily sign an Informed Consent Form (ICF) or
an Informed Assent Form prior to any study-related assessments or procedures being
conducted
- In the investigator's judgment, the individual is willing and able to complete the
protocol-required follow-up schedule and comply with the study requirements for
participation
Exclusion Criteria: none
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kelly Chyan
650-625-8130
I'm interested
Psoriasis Clinical Trials
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: Axicabtagene Ciloleucel
- biological: Brexucabtagene Autoleucel
- biological: KITE-585
- biological: KITE-718
- biological: KITE-439
- biological: KITE-222
- biological: KITE-363
Eligibility
Inclusion Criteria:
- The individual must have received an infusion of gene-modified cells in a completed
Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or
completed the post-treatment follow-up period in the parent study, as applicable
- The individual must understand and voluntarily sign an Informed Consent Form (ICF) or
an Informed Assent Form prior to any study-related assessments or procedures being
conducted
- In the investigator's judgment, the individual is willing and able to complete the
protocol-required follow-up schedule and comply with the study requirements for
participation
Exclusion Criteria: none
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kelly Chyan
650-625-8130
I'm interested
Dermatology Clinical Trials
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: Axicabtagene Ciloleucel
- biological: Brexucabtagene Autoleucel
- biological: KITE-585
- biological: KITE-718
- biological: KITE-439
- biological: KITE-222
- biological: KITE-363
Eligibility
Inclusion Criteria:
- The individual must have received an infusion of gene-modified cells in a completed
Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or
completed the post-treatment follow-up period in the parent study, as applicable
- The individual must understand and voluntarily sign an Informed Consent Form (ICF) or
an Informed Assent Form prior to any study-related assessments or procedures being
conducted
- In the investigator's judgment, the individual is willing and able to complete the
protocol-required follow-up schedule and comply with the study requirements for
participation
Exclusion Criteria: none
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kelly Chyan
650-625-8130
I'm interested
Pediatric Dermatology Clinical Trials
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: Axicabtagene Ciloleucel
- biological: Brexucabtagene Autoleucel
- biological: KITE-585
- biological: KITE-718
- biological: KITE-439
- biological: KITE-222
- biological: KITE-363
Eligibility
Inclusion Criteria:
- The individual must have received an infusion of gene-modified cells in a completed
Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or
completed the post-treatment follow-up period in the parent study, as applicable
- The individual must understand and voluntarily sign an Informed Consent Form (ICF) or
an Informed Assent Form prior to any study-related assessments or procedures being
conducted
- In the investigator's judgment, the individual is willing and able to complete the
protocol-required follow-up schedule and comply with the study requirements for
participation
Exclusion Criteria: none
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kelly Chyan
650-625-8130
I'm interested
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: Axicabtagene Ciloleucel
- biological: Brexucabtagene Autoleucel
- biological: KITE-585
- biological: KITE-718
- biological: KITE-439
- biological: KITE-222
- biological: KITE-363
Eligibility
Inclusion Criteria:
- The individual must have received an infusion of gene-modified cells in a completed
Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or
completed the post-treatment follow-up period in the parent study, as applicable
- The individual must understand and voluntarily sign an Informed Consent Form (ICF) or
an Informed Assent Form prior to any study-related assessments or procedures being
conducted
- In the investigator's judgment, the individual is willing and able to complete the
protocol-required follow-up schedule and comply with the study requirements for
participation
Exclusion Criteria: none
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kelly Chyan
650-625-8130
I'm interested
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: Axicabtagene Ciloleucel
- biological: Brexucabtagene Autoleucel
- biological: KITE-585
- biological: KITE-718
- biological: KITE-439
- biological: KITE-222
- biological: KITE-363
Eligibility
Inclusion Criteria:
- The individual must have received an infusion of gene-modified cells in a completed
Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or
completed the post-treatment follow-up period in the parent study, as applicable
- The individual must understand and voluntarily sign an Informed Consent Form (ICF) or
an Informed Assent Form prior to any study-related assessments or procedures being
conducted
- In the investigator's judgment, the individual is willing and able to complete the
protocol-required follow-up schedule and comply with the study requirements for
participation
Exclusion Criteria: none
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kelly Chyan
650-625-8130
I'm interested